Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Actual. osteol ; 18(1): 10-21, 2022. ilus, tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1395661

ABSTRACT

La periodontitis es una patología inflamatoria que aumenta la resorción de hueso alveolar (HA), pérdida de la inserción dentaria y posible exfoliación. Evaluamos el efecto de la administración intermitente de bajas dosis de parathormona (PTH) 1-34 sobre la recuperación de la masa ósea pérdida en un modelo experimental de periodontitis inducida por una ligadura periodontal (LP) con hilo de algodón alrededor de la pieza dentaria. Las ratas fueron divididas luego de 5 días en instaurada la periodontitis en: CT LP sin trata-miento y PTH LP tratados con 0,2 µg/kg PTH 1-34 subcutánea local, tres veces por semana por 17 días. El control absoluto fue un tercer grupo sin LP (CT). Se estudiaron parámetros antropométricos, bioquímicos e histomosfométricos en tibias y hemimandibulas. La calcemia, fosfatemia, CTX sérico, PTHi y vo-lumen óseo (BV/TV%) de tibias fueron similares en los tres grupos. El BV/TV% del HA fue significativamente menor en PTH LP respecto de CT pero mayor que CT LP (p<0.05). La pérdida ósea de HA porcentual fue significativamente mayor en CT LP (p<0.05). La altura del ligamento periodontal fue significativamente menor en PTH LP que en CT (p<0.05) y mayor respecto de CT LP, sin alcanzar diferencias significativas. Los resultados del presente estudio piloto sugieren que la administración intermitente de PTH en bajas dosis y durante un periodo de tiempo corto disminuye la progresión de la enfermedad periodontal sin generar efectos sistémicos. Como no se logró regenerar totalmente el tejido periodontal se requieren estudios adicionales. (AU)


Periodontitis is an inflammatory chronic disease with high prevalence in adults that induces a progressive alveolar bone (AB) loss leading to tooth loss. Experimental periodontitis can be induced in rats by cotton ligature placement (LP) in the gingival sulcus around the molar teeth. The biofilm accumulation and disruption of the gingival epithelium lead to bone resorption. We investigated whether intermittent administration of a low dose of PTH 1-34 may recover the alveolar bone loss in the experimental periodontitis induced in female Wistar rats. Animals were randomly divided in two groups which were subcutaneously injected with: saline solution (CT LP) or 0,2 µg/kg PTH 1-34 (PTH LP) three times per week during 17 days. Unligated rats were taken as healthy controls (CT). Anthropometric, biochemical and histologic analysis of tibia and hemimandible were done. No differences in serum calcium, phosphorus, CTX, PTHi or subchondral tibia bone volume (BV/TV%) were observed between the three groups. AB BV/TV% was significantly lower in PTH LP than in CT but higher than in CT LP (p<0.05). The highest percentage of AB loss was observed in CT LP. The height of periodontal ligament was lower in PTH LP than in CT (p<0.05) but not significantly higher than CT LP.The increase in AB loss by experimental periodontitis appears to be corrected by the intermittent administration of low doses of PTH without systemic effect. As the recovery of periodontal tissue was only partial, additional studies should be done.


Subject(s)
Animals , Female , Rats , Periodontitis/drug therapy , Alveolar Bone Loss/drug therapy , Teriparatide/administration & dosage , Tibia/anatomy & histology , Tibia/chemistry , Rats, Wistar , Disease Progression , Models, Animal , Mandible/anatomy & histology , Mandible/chemistry
2.
J. appl. oral sci ; 28: e20190140, 2020. tab, graf
Article in English | LILACS, BBO | ID: biblio-1056590

ABSTRACT

Abstract Objective: The goal of the present study was to determine the effect of systemic and topical ozone application on alveolar bone loss (ABL) by evaluating the effect of Hypoxia-inducible factor −1 alpha (HIF-1-α) and receptor activator of NF-kB ligand (RANKL)-positive cells on histopathological and immunohistochemical changes in a rat periodontitis model. Methodology: Thirty male Wistar rats were divided into three groups: 1) Group C (control group); 2) Group SO (systemic ozone group) and 3) Group TO (topical ozone group). Experimental periodontitis was induced with a 3/0 silk suture placed at the mandibular left first molars of rats, and the suture was removed 14 days later. Ozone gas was injected intraperitoneally (0.7 mg/kg) in SO group. Topical ozone application protocol was performed using an ozone generator at 80% concentration (4th grade) 90- degree probe for the duration of 30 s. Both ozone applications were carried out for two weeks at intervals of two days. Histomorphometric and immunohistochemical analysis were performed. Results: ABL was significantly lower in Group SO compared to Group C (p: 0.0052). HIF-1α- positive cells were significantly lower in Group TO than in Group C (p: 0.0043). RANKL-positive cells were significantly lower in Group SO and in Group TO compared to the control group (p: 0.0033, p: 0.0075, respectively). Conclusion: Both ozone applications decreased RANKL-positive cell counts, TO application decreased HIF-1-α positive cells counts, and SO application was found to be more effective in reducing ABL compared to control group.


Subject(s)
Animals , Male , Ozone/administration & dosage , Periodontitis/pathology , Periodontitis/drug therapy , Alveolar Bone Loss/pathology , Alveolar Bone Loss/drug therapy , Hypoxia-Inducible Factor 1, alpha Subunit/analysis , Immunohistochemistry , Cell Count , Reproducibility of Results , Administration, Topical , Treatment Outcome , Rats, Wistar
3.
Braz. oral res. (Online) ; 33: e001, 2019. graf
Article in English | LILACS | ID: biblio-989482

ABSTRACT

Abstract Colchicine is widely used in the treatment of several inflammatory diseases due to its anti-inflammatory effect, but effects on bone metabolism are unclear. The aim of this study was to evaluate the effects of systemically-administered colchicine on healthy periodontium and experimentally-induced periodontitis. In total, 42 male Wistar rats were included in this study. A non-ligated group constituting the negative control group (Control, C, n = 6) and a ligature-only group forming the positive control group (LO, n = 12) were created separately. Twelve rats were treated with 0.4 mg/kg colchicine and another 12 with 1 mg/kg colchicine. In the colchicine-administered groups, right mandibles constituted the ligated groups (1 mgC-L or 0.4 mgC-L) and left mandibles formed the corresponding non-ligated controls (1mgC or 0.4mgC). Silk ligatures were placed at the gingival margin of the lower first molars. The animals were euthanized at different time-points of healing (11 or 30 days). Alveolar bone loss was clinically measured and TRAP+ osteoclasts, osteoblastic activity, and MMP-1 expression were examined histologically. There was no increase in alveolar bone loss with either colchicine dose in healthy periodontium (p > 0.05) and the highest level of alveolar bone loss, TRAP+ osteoclast number, and MMP-1 expression were measured in the LO group (p < 0.05). The 0.4 mgC-L group showed less alveolar bone loss at 11 days (p < 0.05), but greater loss at 30 days. The 1 mgC-L group showed higher osteoblast number than the other ligated groups (p < 0.05) at both time-points. In summary, colchicine did not increase alveolar bone loss in healthy periodontium and also may tend to reduce periodontitis progression. However, further extensive study is necessary to understand the mechanism of colchicine action on alveolar bone loss in periodontitis.


Subject(s)
Humans , Animals , Male , Periodontitis/drug therapy , Colchicine/pharmacology , Alveolar Bone Loss/drug therapy , Anti-Inflammatory Agents/pharmacology , Osteoblasts/drug effects , Osteoclasts/drug effects , Periodontitis/etiology , Periodontitis/pathology , Time Factors , Immunohistochemistry , Colchicine/therapeutic use , Reproducibility of Results , Alveolar Bone Loss/pathology , Treatment Outcome , Rats, Wistar , Matrix Metalloproteinase 1/analysis , Tubulin Modulators/pharmacology , Tartrate-Resistant Acid Phosphatase/analysis , Ligation , Anti-Inflammatory Agents/therapeutic use
4.
J. appl. oral sci ; 27: e20180211, 2019. tab, graf
Article in English | LILACS, BBO | ID: biblio-984568

ABSTRACT

Abstract Objective The aim of this study was to evaluate the effects of gliclazide on oxidative stress, inflammation, and bone loss in an experimental periodontal disease model. Material and Methods Male albino Wistar rats were divided into no ligature, ligature, and ligature with 1, 5, and 10 mg/kg gliclazide groups. Maxillae were fixed and scanned using micro-computed tomography to quantify linear and bone volume/tissue volume (BV/TV) and volumetric bone loss. Histopathological, immunohistochemical and immunofluorescence analyses were conducted to examine matrix metalloproteinase-2 (MMP-2), cyclooxygenase 2 (COX-2), cathepsin K, members of the receptor activator of the nuclear factor kappa-Β ligand (RANKL), receptor activator of nuclear factor kappa-Β (RANK), osteoprotegerin (OPG) pathway, macrophage migration inhibitory factor (MIF), superoxide dismutase-1 (SOD-1), glutathione peroxidase-1 (GPx-1), NFKB p 50 (Cytoplasm), NFKB p50 NLS (nuclear localization signal), PI3 kinase and AKT staining. Myeloperoxidase activity, malondialdehyde and glutathione levels, while interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels were evaluated by spectroscopic ultraviolet-visible analysis. A quantitative reverse transcription polymerase chain reaction was used to quantify the gene expression of the nuclear factor kappa B p50 subunit (NF-κB p50), phosphoinositide 3-kinase (PI3k), protein kinase B (AKT), and F4/80. Results Micro-computed tomography showed that the 1 mg/kg gliclazide treatment reduced linear bone loss compared to the ligature, 5 mg/kg gliclazide, and 10 mg/kg gliclazide treatments. All concentrations of gliclazide increased bone volume/tissue volume (BV/TV) compared to the ligature group. Treatment with 1 mg/kg gliclazide reduced myeloperoxidase activity, malondialdehyde, IL-1β, and TNF-α levels (p≤0.05), and resulted in weak staining for COX-2, cathepsin k, MMP-2, RANK, RANKL, SOD-1, GPx-1,MIF and PI3k. In addition, down-regulation of NF-κB p50, PI3k, AKT, and F4/80 were observed, and OPG staining was strong after the 1 mg/kg gliclazide treatment. Conclusions This treatment decreased neutrophil and macrophage migration, decreased the inflammatory response, and decreased bone loss in rats with ligature-induced periodontitis.


Subject(s)
Animals , Male , Periodontitis/drug therapy , Alveolar Bone Loss/drug therapy , Oxidative Stress/drug effects , Gliclazide/pharmacology , Antioxidants/pharmacology , Periodontitis/pathology , Immunohistochemistry , Random Allocation , Reproducibility of Results , Alveolar Bone Loss/pathology , Fluorescent Antibody Technique , Macrophage Migration-Inhibitory Factors/adverse effects , Tumor Necrosis Factor-alpha/analysis , Rats, Wistar , Peroxidase/analysis , Reverse Transcriptase Polymerase Chain Reaction , Matrix Metalloproteinase 2/analysis , Interleukin-1beta/analysis , RANK Ligand/analysis , Receptor Activator of Nuclear Factor-kappa B/analysis , X-Ray Microtomography , Cathepsin K/analysis , Gingiva/pathology , Gingiva/chemistry , Gliclazide/therapeutic use , Glutathione/analysis , Malondialdehyde/analysis , Neutrophils/drug effects , Antioxidants/therapeutic use
5.
J. appl. oral sci ; 26: e20170451, 2018. graf
Article in English | LILACS, BBO | ID: biblio-893699

ABSTRACT

Abstract Local administration of toll-like receptor 9 (TLR9), agonist cytidine-phosphate-guanosine oligodeoxynucleotide (CpG ODNs), and CD40 ligand (CD40L) can decrease ligature-induced periodontal inflammation and bone loss in wild type (WT) mouse. Objective: This study aimed to explore whether such effect is dependent on TLR9 signaling. Material and Methods: Purified spleen B cells isolated from WT C57BL/6J mice and TLR9 knockout (KO) mice were cultured for 48 hours under the following conditions: CD40L, CpG+CD40L, CpG at low, medium and high doses. We determined B cell numbers using a hemocytometer at 24 h and 48 h. Percentages of CD1dhiCD5+ B cells were detected by flow cytometry. Interleukin-10 (IL-10) mRNA expression and protein secretion were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and by ELISA, respectively. The silk ligature was tied around the maxillary second molars for 14 days, during which the CpG+CD40L mixture or PBS was injected into palatal gingiva on days 3, 6, and 9. Results: For both WT and TLR9 KO mice, CpG significantly induced B cell proliferation, increased IL-10 mRNA expression and protein secretion of IL-10 but reduced CD1dhiCD5+ B cells population; local injection of CpG+CD40L mixture significantly decreased alveolar bone loss and the number of TRAP-positive cells adjacent to the alveolar bone surface, and significantly increased the gingival mRNA expression of IL-10 and decreased RANKL and IFN-γ mRNA expression. Conclusions: These results indicated that CpG plus CD40L decreased periodontal inflammation and alveolar bone loss in a TLR9-independent manner in ligature-induced experimental periodontitis.


Subject(s)
Animals , Oligodeoxyribonucleotides/pharmacology , Periodontitis/drug therapy , Alveolar Bone Loss/drug therapy , CD40 Ligand/pharmacology , Cytidine/pharmacology , Toll-Like Receptor 9/drug effects , Guanine Nucleotides/pharmacology , Reference Values , Time Factors , Enzyme-Linked Immunosorbent Assay , B-Lymphocytes/drug effects , Cells, Cultured , Adjuvants, Immunologic/pharmacology , Reproducibility of Results , Interleukin-10/analysis , Disease Models, Animal , Toll-Like Receptor 9/analysis , Real-Time Polymerase Chain Reaction , Flow Cytometry , Gingiva/drug effects , Gingiva/pathology , Mice, Inbred C57BL
6.
Araçatuba; s.n; 2017. 150 p. ilus, graf.
Thesis in Portuguese | LILACS, BBO | ID: biblio-911532

ABSTRACT

Objetivo: Este estudo avaliou comparativamente a influência dos quimioterápicos 5-fluotouracil (5-FU) e Cisplanina (CIS) para tratamento de câncer no periodonto saudável, sobre a evolução da periodontite experimental (PE) e as funções hepáticas e renais de ratos portadores de PE submetidos ao tratamento com os quimioterápicos 5-FU ou CIS. Materiais e Métodos: foram utilizado 90 ratos machos distribuídos em 6 grupos. Grupo SPE-SS (n = 15): animais que receberam injeções de 0,5 ml de solução salina 0.9% (SS) sem indução da PE (grupo Sham). Grupo PE-SS (n = 15): animais que receberam injeções s de 0,5 ml de SS e indução da PE após a primeira injeção. Grupo SPE-5FU (n=15): animais que receberam injeções de 5-Fluorouracil (5- FU) sem indução da PE. Grupo PE-5FU (n = 15): animais que receberam injeções de 5- FU e indução da PE após a primeira injeção. Grupo SPE-CIS (n = 15): animais que receberam injeções Cisplatinas (CIS) sem indução da PE. Grupo PE-CIS (n = 15): animais que receberam injeções de CIS e indução da PE após a primeira injeção. Para indução da PE foi adaptado um fio de algodão número 24 ao redor dos primeiros molares inferiores direito e esquerdo. Decorridos 07, 15 e 30 dias após a primeira injeção intraperitoneal (SS ou quimioterápicos) os animais foram eutanaziados. Foi realizada coleta sanguínea para análises hematológia e bioquímicas de aspartato aminotransferase (AST), alamina aminotransferase (ALT), creatinina e uréia previamente as injeções e aos 07 e 30 dias, totalizando 60 dos 90 ratos. Foram coletadas as mandíbulas contendo os primeiros molares inferiores e processadas de acordo com as análises propostas. Para a análise fotométrica avaliou-se a perda óssea alveolar ao redor do primeiro molar inferior. Para a análise de microtomografia computadorizada (µCT) avaliou-se a porcentagem de volume de tecido ósseo (PVTO) na região de furca. As hemimandíbulas contralaterais foram utilizadas para análises histomorfométrica e imunoistoquímicas na região de furca e avaliou-se a porcentagem de área sem osso (PASO), características histológicas e análises dos biomarcadores (TRAP, RANKL, OPG, TNF-α, IL-1ß, PCNA, BAX e HIF-1α,). Os dados obtidos foram submetidos à análise estatística (p<0,05). Resultado: ambos os quimioterápicos 5-FU e CIS contribuíram para o agravamento da evolução da PE por duas vias: aumentando a intensidade e duração do processo inflamatório; e diminuindo a capacidade de reparo tecidual por redução do "turnover" celular e vascular, resultando de forma significativa na maior perda óssea, que comparativamente foi maior nos animais que receberam aplicação sistêmica de 5-FU do que de CIS. Adicionalmente a PE associada ao 5-FU apresentou de maneira significante maiores níveis de ALT e AST aos 30 dias e associada a CIS apresentou de maneira significante maiores níveis de Uréia e não apresentou diferença significativa nos níveis de Creatinina. Conclusão: ambos os quimioterápicos, 5-FU ou CIS, exacerbaram a severidade da periodontite, sendo que os danos periodontais causadas pelo 5-FU foram comparativamente maiores e mais intensos do que os causados pela CIS. Adicionalmente, podemos concluir que a PE agravou de forma sinérgica as condições debilitantes hepáticas e renais ocasionadas pelos quimioterápicos(AU)


Objective: This study evaluated the influence of chemotherapy with 5-fluorotouracil (5- FU) and Cisplanin (CIS) for the treatment of cancer in healthy periodontium, on the evolution of experimental periodontitis (EP), and liver and kidney function of rats with EP treated with chemotherapeutic agents. Materials and Methods: 90 male rats were distributed in 6 groups. Group SPE-SS (n = 15): animals that received injections of 0.5 ml of 0.9% saline solution (SS) without PE induction (Sham group). Group PE-SS (n = 15): animals that received injections s of 0.5 ml of SS and induction of PE after the first injection. Group SPE-5FU (n = 15): animals receiving injections of 5-Fluorouracil (5- FU) without induction of PE. Group PE-5FU (n = 15): animals receiving injections of 5- FU and induction of PE after the first injection. SPE-CIS group (n = 15): animals that received Cisplatin injections (CIS) without PE induction. PE-CIS group (n = 15): animals that received CIS injections and PE induction after the first injection. For EP induction a cotton thread number 24 was fitted around the first right and left lower first molars. After 07, 15 and 30 days after the first intraperitoneal injection (SS or chemotherapeutic) the animals were euthanized. Blood samples were collected for hematological and biochemical analyzes of AST, ALT, creatinine and urea before injections and at 07 and 30 days. The mandibles containing the mandibular first molars were collected and processed according to the proposed analyzes. For the photometric analysis, alveolar bone loss (ABL) around the lower first molar was evaluated. For the analysis of computerized microtomography (µCT) the percentage of bone tissue volume (PBTV) in the furcation region was evaluated. The contralateral hemimandibula were used for histomorphometric and immunohistochemical analyzes in the furcation region and the percentage of bone-free area (PBFA), histological characteristics and biomarkers analysis (TRAP, RANKL, OPG, TNF-α, IL-1ß, PCNA, BAX and HIF-1α). Data were submitted to statistical analysis (p <0.05). Results: Both chemotherapy 5-FU and CIS contributed to the worsening of the evolution of EP by two routes: increasing the intensity and duration the inflammatory process; and decreased tissue repair ability by reducing cell and vascular turnover, resulting in significantly greater bone loss, which was comparatively higher in animals treated with 5-FU than in CIS. Additionally, 5-FU associated PE significantly increased ALT and AST levels at 30 days and associated CIS significantly increased Urea levels and showed no significant difference in Creatinine levels. Conclusion: both chemotherapy, 5-FU or CIS, exacerbated the severity of periodontitis, and periodontal damage caused by 5-FU was comparatively bigger and faster than those caused by CIS. In addition, we can conclude that PE has synergistically aggravated the liver and kidney debilitating conditions caused by chemotherapy(AU)


Subject(s)
Animals , Rats , Alveolar Bone Loss , Alveolar Bone Loss/drug therapy , Periodontitis , Periodontitis/drug therapy , Furcation Defects , Periodontal Diseases , Pharmaceutical Preparations
7.
J. appl. oral sci ; 23(1): 33-41, Jan-Feb/2015. graf
Article in English | LILACS, BBO | ID: lil-741589

ABSTRACT

Objectives Sumac (Rhus coriaria L.) is widely used spice which has several properties such as antioxidant, anti-inflammatory and antimicrobial. The purpose of this animal study was to evaluate the effects of sumac extract on levels of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG) expression, serum oxidative status, and alveolar bone loss in experimental periodontitis. Material and Methods Twenty-four Wistar rats were separated into three groups: non-ligated (NL, n=8), ligature only (LO, n=8), and ligature and treated with sumac extract (S, n=8) (20 mg/kg per day for 11 days). A 4/0 silk suture was placed around the mandibular right first molars subgingivally; after 11 days, the rats were sacrificed, and alveolar bone loss was histometrically measured. The detection of RANKL and OPG were immunohistochemically performed. Levels of serum total antioxidant status (TAS)/total oxidant status (TOS), and oxidative stress index (OSI) were also analyzed. Results Alveolar bone loss was significantly greater in the LO group compared to the S and NL groups (p<0.05). The number of inflammatory cell infiltrate (ICI) and osteoclasts in the LO group was significantly higher than that of the NL and S groups (p<0.05). The number of osteoblasts in the LO and S groups was significantly higher than that of the NL group (p<0.05). There were significantly more RANKL-positive cells in the LO group than in the S and NL groups (p<0.05). OPG-positive cells were higher in S group than in LO and NL groups (p<0.05). TOS and OSI levels were significantly reduced in S group compared to LO group (P<0.05) and TAS levels were similar in S and NL group (p>0.05). Conclusions The present study showed that systemic administration of sumac extract may reduce alveolar bone loss by affecting RANKL/OPG balance, TOS and OSI levels in periodontal disease in rats. .


Subject(s)
Animals , Male , Alveolar Bone Loss/drug therapy , Osteoprotegerin/drug effects , Oxidative Stress/drug effects , Periodontitis/drug therapy , Plant Extracts/pharmacology , RANK Ligand/drug effects , Rhus/chemistry , Alveolar Bone Loss/pathology , Antioxidants/analysis , Cell Count , Immunohistochemistry , Osteoblasts , Osteoprotegerin/analysis , Oxidants/blood , Periodontitis/pathology , RANK Ligand/analysis , Random Allocation , Rats, Wistar , Reproducibility of Results
8.
Braz. oral res ; 26(2): 158-164, Mar.-Apr. 2012. ilus
Article in English | LILACS | ID: lil-622912

ABSTRACT

The aim of this study was to evaluate the effect of an organic extract obtained from Ipomoea alba L. (Convolvulaceae or OE 1493), on experimental periodontal disease in rats. Periodontitis was induced in thirty six Wistar rats: a first mandibular molar was randomly assigned to receive a ligature, whereas the contralateral molar was left unligated. Animals were randomly assigned to two groups and treated topically, three times a day, for 11 days, as follows: Control Group - vehicle-treated (n = 18), and Test Group - OE 1493-treated (n = 18). The rats were sacrificed on the 12th day. Morphometrical measurements from the cementoenamel junction to the bone crest were performed to determine alveolar bone loss, using standardized photographs. Single- and multi-dose acute toxicity assays were carried out after OE 1493 treatment. Morphometrical analysis demonstrated that topically-administered OE 1493 showed no effect on reducing bone loss when compared with the control group (p > 0.05). In addition, OE 1493 did not present toxicity. Within the limits of this investigation, it may be concluded that OE 1493 did not show any positive influence on the progression of ligature-induced periodontitis in rats, when administered according to the regimen used in the present study.


Subject(s)
Animals , Male , Rats , Ipomoea/chemistry , Phytotherapy , Periodontitis/drug therapy , Plant Extracts/therapeutic use , Alveolar Bone Loss/drug therapy , Disease Models, Animal , Disease Progression , Random Allocation , Rats, Wistar , Time Factors
9.
J. appl. oral sci ; 18(3): 237-243, May-June 2010. ilus, tab
Article in English | LILACS | ID: lil-557086

ABSTRACT

OBJECTIVE: The aim of this study was to assess radiographically the effect of photodynamic therapy (PDT) as an adjunctive treatment to scaling and root planing (SRP) on induced periodontitis in dexamethasone-induced immunosuppressed rats. MATERIAL AND METHODS: The animals were divided into 2 groups: ND group (n=60): saline treatment; D group (n=60): dexamethasone treatment. In both ND and D groups, periodontal disease was induced by the placement of a ligature in the left first mandibular molar. After 7 days, ligature was removed and all animals received SRP, being divided according to the following treatments: SRP: saline and PDT: phenothiazinium dye (TBO) plus laser irradiation. Ten animals per treatment were killed at 7, 15 and 30 days. The distance between the cementoenamel junction and the height of the alveolar bone crest in the mesial surface of the mandibular left first molars was determined in millimeters in each radiograph. he radiographic values were analyzed statistically by ANOVA and Tukey's test at a p value <0.05. RESULTS: Intragroup radiographic assessment (ND and D groups) showed that there was statistically signifcant less bone loss in the animals treated with PDT in all experimental periods compared to those submitted to SRP. Intergroup radiographic analysis (ND and D groups) demonstrated that there was greater bone loss in the ND group treated with SRP compared to the D group treated with PDT at 7 and 30 days. CONCLUSION: PDT was an effective adjunctive treatment to SRP on induced periodontitis in dexamethasone-induced immunosuppressed rats.


Subject(s)
Animals , Male , Rats , Alveolar Bone Loss , Immunocompromised Host , Photochemotherapy , Periodontitis , Alveolar Bone Loss/drug therapy , Alveolar Bone Loss/therapy , Alveolar Process , Combined Modality Therapy , Dental Scaling , Dexamethasone/adverse effects , Furcation Defects/drug therapy , Furcation Defects , Furcation Defects/therapy , Glucocorticoids/adverse effects , Immunosuppressive Agents/adverse effects , Low-Level Light Therapy , Lasers, Semiconductor/therapeutic use , Mandible , Molar , Periodontitis/drug therapy , Periodontitis/therapy , Photosensitizing Agents/therapeutic use , Random Allocation , Rats, Wistar , Root Planing , Time Factors , Tolonium Chloride/therapeutic use , Tooth Cervix
10.
Braz. j. med. biol. res ; 40(1): 117-125, Jan. 2007. ilus, graf
Article in English | LILACS | ID: lil-439676

ABSTRACT

We investigated the effect of etoricoxib, a selective cyclooxygenase-2 inhibitor, and indomethacin, a non-selective cyclooxygenase inhibitor, on experimental periodontitis, and compared their gastrointestinal side effects. A ligature was placed around the second upper left molars of female Wistar rats (160 to 200 g). Animals (6 per group) were treated daily with oral doses of 3 or 9 mg/kg etoricoxib, 5 mg/kg indomethacin, or 0.2 mL saline, starting 5 days after the induction of periodontitis, when bone resorption was detected, until the sacrifice on the 11th day. The weight and survival rate were monitored. Alveolar bone loss (ABL) was measured as the sum of distances between the cusp tips and the alveolar bone. The gastric mucosa was examined macroscopically and the periodontium and gastric and intestinal mucosa were examined by histopathology. The ongoing ABL was significantly inhibited (P < 0.05) by 3 and 9 mg/kg etoricoxib and by indomethacin: control = 4.08 ± 0.47 mm; etoricoxib (3 mg/kg) = 1.89 ± 0.26 mm; etoricoxib (9 mg/kg) = 1.02 ± 0.14 mm; indomethacin = 0.64 ± 0.15 mm. Histopathology of periodontium showed that etoricoxib and indomethacin reduced inflammatory cell infiltration, ABL, and cementum and collagen fiber destruction. Macroscopic and histopathological analysis of gastric and intestinal mucosa demonstrated that etoricoxib induces less damage than indomethacin. Animals that received indomethacin presented weight loss starting on the 7th day, and higher mortality rate (58.3 percent) compared to etoricoxib (0 percent). Treatment with etoricoxib, even starting when ABL is detected, reduces inflammation and cementum and bone resorption, with fewer gastrointestinal side effects.


Subject(s)
Animals , Female , Rats , Cyclooxygenase Inhibitors/therapeutic use , Gastric Mucosa/drug effects , Indomethacin/therapeutic use , Intestinal Mucosa/drug effects , Periodontitis/drug therapy , Pyridines/therapeutic use , Sulfones/therapeutic use , Alveolar Bone Loss/drug therapy , Rats, Wistar
11.
Braz. oral res ; 21(3): 241-246, 2007. tab
Article in English | LILACS | ID: lil-458597

ABSTRACT

The objective of this split-mouth, double-blind, randomized controlled trial was to compare the clinical effect of treatment of 2- or 3-wall intrabony defects with open flap debridement (OFD) combined or not with enamel matrix proteins (EMP). Thirteen volunteers were selected with one pair of or more intrabony defects and probing pocket depth (PPD) > 5 mm. All individuals received instructions regarding oral hygiene and were submitted to scaling and root planing. Each participant received the two treatment modalities: test sites were treated with OFD and EMP, and control sites received only OFD. After 6 months, a significant reduction was observed in PPD for the EMP group (from 6.42 ± 1.08 mm to 2.67 ± 1.15 mm) and for the OFD group (from 6.08 ± 1.00 mm to 2.00 ± 0.95 mm) (p < 0.0001), but with no significant difference between groups (p = 0.13). A significant gain in relative attachment level (RAL) was observed in both groups (EMP: from 13.42 ± 1.88 mm to 10.75 ± 2.26 mm, p < 0.001; OFD: from 12.42 ± 1.98 mm to 10.58 ± 2.23 mm, p = 0.013), but with no significant difference between groups (p = 0.85). Gingival recession (GR) was higher in the EMP group (from 1.08 ± 1.50 mm to 2.33 ± 1.43 mm; p = 0.0009) than in the OFD group (from 0.66 ± 1.15 mm to 1.16 ± 1.33 mm; p = 0.16), but this difference was not significant (p = 0.06). In conclusion, the results showed that OFD combined with EMP was not able to improve treatment of intrabony defects compared to OFD alone.


O objetivo deste estudo clínico controlado, randomizado, duplo-cego, tipo boca-dividida foi comparar o efeito clínico do tratamento de defeitos infra-ósseos de 2 ou 3 paredes com retalho de espessura total (RET) associado ou não com a proteína da matriz do esmalte (PME). Treze voluntários com 1 par ou mais de defeitos infra-ósseos foram selecionados com profundidade clínica de sondagem (PCS) > 5 mm. Todos receberam instruções de higiene bucal, raspagem e alisamento radicular. Cada participante recebeu os dois tipos de tratamento: o lado teste foi tratado com RET e PME, e o lado controle recebeu somente RET. Após 6 meses, foi observada uma redução significante na PCS para o grupo PME (de 6,42 ± 1,08 mm para 2,67 ± 1,15 mm) e para o grupo RET (de 6,08 ± 1,00 mm para 2,00 ± 0,95 mm) (p < 0,0001), mas não houve diferença significante entre os grupos (p = 0,13). Um ganho significante de nível clínico de inserção relativo (NCIR) foi observado em ambos os grupos (PME: de 13,42 ± 1,88 mm para 10,75 ± 2,26 mm, p < 0,001; RET: de 12,42 ± 1,98 mm para 10,58 ± 2,23 mm, p = 0,013), mas não houve diferença significante entre os grupos (p = 0,85). A retração gengival (RG) foi maior para o grupo PME (de 1,08 ± 1,50 mm para 2,33 ± 1,43 mm; p = 0,0009) do que para o grupo RET (de 0,66 ± 1,15 mm para 1,16 ± 1,33 mm; p = 0,16), mas essa diferença não foi significante (p = 0,06). Concluiu-se que o tratamento de defeitos infra-ósseos com RET associado à PME não mostrou resultados melhores que o uso de RET sozinho.


Subject(s)
Adult , Female , Humans , Male , Alveolar Bone Loss/drug therapy , Alveolar Bone Loss/surgery , Bone Regeneration/drug effects , Debridement , Dental Enamel Proteins/pharmacology , Surgical Flaps , Combined Modality Therapy/methods , Dental Plaque Index , Double-Blind Method , Dental Enamel Proteins/therapeutic use , Follow-Up Studies , Gingival Recession/drug therapy , Gingival Recession/surgery , Periodontal Attachment Loss/drug therapy , Periodontal Attachment Loss/surgery , Tooth Root/drug effects
12.
Braz. oral res ; 21(3): 247-252, 2007. tab, graf, ilus
Article in English | LILACS | ID: lil-458598

ABSTRACT

Bisphosphonates are currently used in the treatment of many diseases involving increased bone resorption such as osteoporosis. Statins have been widely used for the treatment of hypercholesterolemia and recent studies have shown that these drugs are also capable of stimulating bone formation. The purpose of this study was to evaluate the influence of an estrogen deficient state and the effects of simvastatin and sodium alendronate therapies on alveolar bone in female rats. Fifty-four rats were either ovariectomized (OVX) or sham operated. A month later, the animals began to receive a daily dose of simvastatin (SIN - 25 mg/kg), sodium alendronate (ALN - 2 mg/kg) or water (control) orally. Thirty-five days after the beginning of the treatment, the rats were sacrificed and their left hemimandibles were removed and radiographed using digital X-ray equipment. The alveolar radiographic density under the first molar was determined with gray-level scaling and the values were submitted to analysis of variance (a = 5 percent). Ovariectomized rats gained more weight (mean ± standard deviation: 20.06 ± 6.68 percent) than did the sham operated animals (12.13 ± 5.63 percent). Alveolar radiographic density values, expressed as gray levels, were lowest in the OVX-water group (183.49 ± 6.47), and differed significantly from those observed for the groups receiving alendronate (sham-ALN: 193.85 ± 3.81; OVX-ALN: 196.06 ± 5.11) and from those of the sham-water group (193.66 ± 4.36). Other comparisons between groups did not show significant differences. It was concluded that the ovariectomy reduced alveolar bone density and that alendronate was efficient for the treatment of this condition.


Os bisfosfonatos são empregados atualmente para o tratamento de várias doenças caracterizadas pelo aumento da reabsorção óssea, como a osteoporose. As estatinas são amplamente utilizadas para redução de níveis elevados de colesterol e estudos recentes têm revelado sua ação anabólica no osso. O objetivo deste trabalho foi avaliar a influência da deficiência estrogênica e dos tratamentos com sinvastatina ou alendronato sódico no osso alveolar em ratas. Cinqüenta e quatro ratas sofreram ovariectomia (OVX) ou cirurgia simulada ("sham"). Um mês após, os animais passaram a receber diariamente, via oral, 25 mg/kg de sinvastatina (SIN), 2 mg/kg de alendronato (ALN) ou água (controle). Trinta e cinco dias depois do início do tratamento os animais foram sacrificados, as hemimandíbulas esquerdas removidas e radiografadas em aparelho de raios X digital. Foi calculada a densidade radiográfica em tons de cinza da área de osso alveolar sob o primeiro molar mandibular e os valores foram submetidos a ANOVA, ao nível de 5 por cento. Ratas ovariectomizadas ganharam mais peso (média ± desvio-padrão: 20,06 ± 6,68 por cento) que as demais (12,13 ± 5,63 por cento). Os valores de densidade radiográfica, em tons de cinza, foram menores nos animais do grupo OVX-água (183,49 ± 6,47), significantemente diferentes daqueles observados nos grupos que receberam alendronato ("sham"-ALN: 193,85 ± 3,81; OVX-ALN: 196,06 ± 5,11) e no grupo "sham"-água (193,66 ± 4,36). Outras comparações entre grupos não revelaram diferenças estatísticas. Concluiu-se que a ovariectomia reduziu a densidade óssea alveolar e que o tratamento com alendronato sódico foi eficiente para o tratamento desta situação.


Subject(s)
Animals , Female , Rats , Alveolar Bone Loss/drug therapy , Hypolipidemic Agents/therapeutic use , Bone Density Conservation Agents/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Ovariectomy , Osteoporosis/drug therapy , Analysis of Variance , Alendronate/therapeutic use , Alveolar Process/drug effects , Hypolipidemic Agents/administration & dosage , Bone Density , Disease Models, Animal , Drug Evaluation, Preclinical , Estrogens/deficiency , Hypercholesterolemia/drug therapy , Mandible/drug effects , Random Allocation , Rats, Wistar , Simvastatin/therapeutic use
13.
ACES-Actualites Cliniques et Scientifiques. 2003; 24 (1): 6-20
in French | IMEMR | ID: emr-61285

ABSTRACT

The enamel matrix derivative [EMD] has been introduced in 1997 for the regeneration of intrabony periodontal defects. The aim of the present review is to study its clinical and histological efficacy. Material and methods: 33 clinical trials and 8 histological investigations on the efficacy of EMD in the treatment of intrabony defects have reviewed. A meta-analytic approach has been adopted in analyzing the clinical attachment gain and the gingival recession by weighing the outcomes of each study in relation to the number of treated defects. The weighted mean of the clinical attachment gain amounted to 3.1 mm for 403 compiled defects. Gingival recession amounted to 1 mm for 265 compiled defects. Bone fill of the original defect varied between 0.8 mm and 4.8 mm. Despite the overall efficacy of EMD, a significant variation in clinical outcomes was observed. Histologicaly, of 28 chronic human intrabony defects compiled, 54% presented regeneration, 24% new connective tissue attachment and 25% long junctional epithelium. Considering the variations observed in clinical and histological outcome, further randomized controlled clinical trial with adequate statistical power one needed in orcler to clarify the efficacy and the predictability of the EMD treatment


Subject(s)
Humans , Alveolar Bone Loss/drug therapy , Periodontal Diseases/drug therapy , Gingival Recession , Bone Regeneration , Meta-Analysis
SELECTION OF CITATIONS
SEARCH DETAIL